

Shakeel Modak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5879541/publications.pdf>

Version: 2024-02-01

56
papers

2,703
citations

218677

26
h-index

189892

50
g-index

57
all docs

57
docs citations

57
times ranked

4253
citing authors

#	ARTICLE	IF	CITATIONS
1	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020, 182, 1044-1061.e18.	28.9	691
2	Neuroblastoma: Therapeutic strategies for a clinical enigma. <i>Cancer Treatment Reviews</i> , 2010, 36, 307-317.	7.7	141
3	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 2433-2441.	7.0	134
4	Anti-GD2 immunotherapy for neuroblastoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 889-904.	2.4	128
5	Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 1934-1943.	1.6	123
6	Disialoganglioside Directed Immunotherapy of Neuroblastoma. <i>Cancer Investigation</i> , 2007, 25, 67-77.	1.3	105
7	Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. <i>PLoS Genetics</i> , 2016, 12, e1006501.	3.5	98
8	Humanized 3F8 Anti-G _{D2} Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma. <i>JAMA Oncology</i> , 2018, 4, 1729.	7.1	86
9	Rituximab therapy of lymphoma is enhanced by orally administered (1 α '3),(1 α '4)-d- β -glucan. <i>Leukemia Research</i> , 2005, 29, 679-683.	0.8	75
10	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021, 2, 357-365.	13.2	74
11	A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26409.	1.5	66
12	Management of desmoplastic small round cell tumor. <i>Seminars in Pediatric Surgery</i> , 2016, 25, 299-304.	1.1	62
13	Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression. <i>Journal of Clinical Oncology</i> , 2021, 39, 215-226.	1.6	60
14	Disialoganglioside G _{D2} and a novel tumor antigen: Potential targets for immunotherapy of desmoplastic small round cell tumor. <i>Medical and Pediatric Oncology</i> , 2002, 39, 547-551.	1.0	54
15	Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G _{D2} immunotherapy and isotretinoin: a prospective Phase II study. <i>Oncolmmunology</i> , 2015, 4, e1016704.	4.6	52
16	Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. <i>Oncotarget</i> , 2016, 7, 4155-4166.	1.8	51
17	Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. <i>Oncolmmunology</i> , 2018, 7, e1461305.	4.6	49
18	Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26448.	1.5	44

#	ARTICLE	IF	CITATIONS
19	A phase I/II trial targeting the Pi3k/Akt pathway using perifosine: long-term progression-free survival of patients with resistant neuroblastoma. <i>International Journal of Cancer</i> , 2017, 140, 480-484.	5.1	41
20	B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4283-4291.	1.6	40
21	A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. <i>PLoS ONE</i> , 2017, 12, e0178593.	2.5	38
22	Transient sialoadenitis: A complication of ¹³¹ I-metaiodobenzylguanidine therapy. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1271-1273.	1.5	36
23	Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 393-400.	0.8	36
24	Radioimmunotargeting of Human Rhabdomyosarcoma Using Monoclonal Antibody 8H9. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 534-546.	1.0	35
25	Germline SDHA mutations in children and adults with cancer. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002584.	1.2	33
26	Anti-GD2 antibody 3F8 and barley-derived (1 → 3), (1 → 4)-β-D-glucan. <i>Oncolmmunology</i> , 2013, 2, e234024.6	2.6	30
27	Plerixafor plus granulocyte colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2012, 58, 469-471.	1.5	26
28	Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. <i>Oncolmmunology</i> , 2017, 6, e1358331.	4.6	25
29	Treatment and outcome of adult-onset neuroblastoma. <i>International Journal of Cancer</i> , 2018, 143, 1249-1258.	5.1	23
30	Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor. <i>Sarcoma</i> , 2015, 2015, 1-9.	1.3	21
31	Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1204-1209.	0.8	19
32	Feasibility of Administering High-Dose ¹³¹ I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms. <i>Pediatric Blood and Cancer</i> , 2016, 63, 801-807.	1.5	17
33	Arsenic Trioxide as a Radiation Sensitizer for ¹³¹ I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 231-237.	5.0	17
34	Dose escalation is needed for gross disease in high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27009.	1.5	17
35	Osteochondroma in long-term survivors of high-risk neuroblastoma. <i>Cancer</i> , 2015, 121, 2090-2096.	4.1	15
36	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. <i>Molecular Cancer Research</i> , 2021, 19, 1146-1155.	3.4	14

#	ARTICLE	IF	CITATIONS
37	Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 409-414.	0.8	13
38	Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, e381-e383.	0.6	10
39	Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26549.	1.5	10
40	MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy. <i>Oncotarget</i> , 2017, 8, 95293-95302.	1.8	10
41	A novel image-based system for risk stratification in patients with desmoplastic small round cell tumor. <i>Journal of Pediatric Surgery</i> , 2020, 55, 376-380.	1.6	9
42	Antibody-based targeted radiation to pediatric tumors. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 157S-63S.	5.0	8
43	Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass. <i>Journal of Pediatric Surgery</i> , 2016, 51, 285-288.	1.6	7
44	Nivolumab in paediatric cancer: children are not little adults. <i>Lancet Oncology</i> , The, 2020, 21, 474-476.	10.7	7
45	Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28364.	1.5	7
46	Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29265.	1.5	7
47	F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 3179-3188.	2.1	7
48	Differential Impact of ALK Mutations in Neuroblastoma. <i>JCO Precision Oncology</i> , 2021, 5, 492-500.	3.0	6
49	Phase I Trial of Oral Yeast-Derived Î²-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. <i>Cancers</i> , 2021, 13, 6265.	3.7	6
50	Assessment of pulmonary outcomes, exercise capacity, and longitudinal changes in lung function in pediatric survivors of high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27960.	1.5	5
51	Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, e257-e259.	0.6	4
52	Mandibular metastases in neuroblastoma: Outcomes and dental sequelae. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28918.	1.5	4
53	Reply to K. Satharasinghe et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e235-e235.	1.6	2
54	Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26314.	1.5	2

#	ARTICLE	IF	CITATIONS
55	Updates in the treatment of neuroblastoma. Clinical Advances in Hematology and Oncology, 2011, 9, 74-6.	0.3	2
56	Is Extended Sedation Necessary for Young Children Receiving High-Dose ¹³¹ I-MIBG Therapy?. Pediatric Blood and Cancer, 2016, 63, 1867-1867.	1.5	1